SGLT1/SGLT2双重抑制剂索格列净用于1型糖尿病的研究进展

Research advances of sotagliflozin——a dual inhibitor of SGLT1 and SGLT2 in treating type 1 diabetes

索格列净是一种SGLT1/SGLT2双重抑制剂,具有独特的非胰岛素依赖型降糖机制,可通过抑制SGLT2而增加经肾葡萄糖的排出,也可以通过抑制SGLT1而减少经胃肠道入血的葡萄糖。已有的临床研究证明索格列净对2型糖尿病和1型糖尿病均有疗效,而国内多是其用于2型糖尿病的研究报道。本文重点总结了三项索格列净Ⅲ期临床试验(inTandem1、 inTandem2、 inTandem3)的最新研究结果,阐述索格列净作为胰岛素辅助疗法用于治疗1型糖尿病的作用机制及临床研究进展。

Sotagliflozin,a dual inhibitor of SGLT1 and SGLT2,provides complementary insulin-independent hypoglycemic mechanism.It acts by inhibiting renal SGLT2 to increase urinary glucose excretion and by inhibiting intestinal SGLT1 to reduce the absorption of dietary glucose.Existing clinical studies have proved its effect on type 1 diabetes and type 2 diabetes.The domestic reports are mostly for type 2 diabetes,with limited systematic reviews for type 1 diabetes.In this paper,three phase Ⅲ clinical trials of sotagliflozin（ inTandem1,inTandem2,inTandem3） are emphatically reviewed in order to expound action mechanism and clinical research advances of sotagliflozin as adjunct therapy to insulin for type 1 diabetes.